Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $216,539.40 in Stock

Key Points

• Bicara Therapeutics CEO Claire Mazumdar sold $216,539.40 worth of stock, reducing her ownership by 3.56%, leaving her with approximately 309,892 shares valued at $5.86 million.
• The stock price of Bicara Therapeutics increased by $1.50 during mid-day trading to reach $18.81, having a market capitalization of $1.03 billion and a PE ratio of -5.93.
• Analysts have mixed ratings on Bicara Therapeutics, with a consensus "Moderate Buy" rating and an average target price of $31.86, despite one sell rating from Weiss Ratings.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 11,445 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $18.92, for a total transaction of $216,539.40. Following the completion of the sale, the chief executive officer directly owned 309,892 shares of the company's stock, valued at $5,863,156.64. This represents a 3.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, October 15th, Claire Mazumdar sold 13,289 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total value of $250,364.76.

Bicara Therapeutics Stock Performance

BCAX stock traded up $1.50 during mid-day trading on Wednesday, reaching $18.81. 700,861 shares of the stock traded hands, compared to its average volume of 581,907. The business has a 50-day moving average price of $12.77 and a two-hundred day moving average price of $11.92. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $28.09. The stock has a market capitalization of $1.03 billion and a PE ratio of -5.93.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds have recently made changes to their positions in BCAX. Nuveen LLC acquired a new position in Bicara Therapeutics in the 1st quarter valued at $326,000. New York State Common Retirement Fund acquired a new position in Bicara Therapeutics in the 1st quarter valued at $52,000. GAMMA Investing LLC increased its stake in Bicara Therapeutics by 13,040.7% in the 1st quarter. GAMMA Investing LLC now owns 7,753 shares of the company's stock valued at $101,000 after buying an additional 7,694 shares during the period. CWM LLC acquired a new position in Bicara Therapeutics during the 1st quarter worth approximately $29,000. Finally, Atle Fund Management AB increased its position in Bicara Therapeutics by 23.0% during the 2nd quarter. Atle Fund Management AB now owns 147,380 shares of the company's stock worth $1,369,000 after purchasing an additional 27,547 shares during the period.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. HC Wainwright cut their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Tuesday. Finally, Piper Sandler started coverage on Bicara Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.